Prediction of hepatic clearance in human from in vitro data for successful drug development. - Wikidata - wikimedia - TriplyDB

Prediction of hepatic clearance in human from in vitro data for successful drug development.

Prediction of hepatic clearance in human from in vitro data for successful drug development.

http://www.wikidata.org/entity/Q33437736

about

An update on the role of intestinal cytochrome P450 enzymes in drug disposition Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (-/-) rats into absorption study of multiple transporter substrate In vitro platforms for evaluating liver toxicity.Drug structure-transport relationships Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.Applications of human pharmacokinetic prediction in first-in-human dose estimation Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Applications of minimal physiologically-based pharmacokinetic models.Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates Applicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties Knowledge-driven approaches for the guidance of first-in-children dosing.The effects of obesity on drug pharmacokinetics in humans.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.An evaluation of the latest in vitro tools for drug metabolism studies.The role of drug metabolizing enzymes in clearance.Discovery and preclinical development of new antibiotics.The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio.Predictions of bisphenol A hepatic clearance in the isolated perfused rat liver (IPRL): impact of albumin binding and of co-administration with naproxen.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective.A microfluidic hepatic coculture platform for cell-based drug metabolism studies.Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine.Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.

P2860

Q28079725-0AEE0E6C-0DD7-46BB-94B5-2D83D64F0DEF Q28577650-A7E086AB-62E6-45C2-9F6F-A2F44F6188A2 Q34143314-46A9F9F7-2FF0-4041-A537-7EC43B82E8A9 Q34420259-61860188-E541-44A2-8AEA-88CB308D4060 Q35166429-2250502A-605F-4CE8-8791-3A2DFD10EFC2 Q35264818-A5B9A29E-5B7B-4AA3-AC66-1E62CF238DA6 Q35653564-AAED49F1-A44C-473C-97B9-70E7B0B5CDB3 Q35745230-A15EDC11-5350-46AC-882A-BAF0AD19B148 Q35826421-FBFD8827-9AE1-4F62-B011-B16833BD82CA Q35888391-FECD2F98-DFDF-4DCA-94E8-A4F6486B28C9 Q36243653-45CE4DF3-875A-4715-8B1B-6B9940E53EEE Q36517093-A7CFA916-259C-4A91-9DFB-AFCE2A4DF108 Q36631747-ADBA4557-EF08-4E8C-84E9-8CAF612FCB71 Q36735906-75E17605-5DE8-4558-98ED-0E2AEF2BA5B4 Q36947707-510C260F-2D8C-4B05-BA22-502812DF8CF5 Q37193103-04ABB247-341C-4D32-B460-7AE98B6C1D1A Q37210032-D4067770-38E1-4A9D-BDCB-2101260B5BCA Q37694333-BBBE3E8D-8431-403F-B871-28A662F9605F Q37815555-1F1D32D0-DCA0-4B4E-9F3A-43EC1C1128FE Q37854751-B88ACCB0-23C5-4D3D-8577-49E6BA98602B Q38016204-EA2E99E4-C1B9-4A1F-9A47-21B7C40DA233 Q38131859-060011D5-0AD9-48CF-A8B7-86B82F67DC97 Q38151571-13BFB879-AE13-47CE-9132-B16DB00AE155 Q38160881-4BD1E8A2-7914-46B2-9279-903B5465948A Q38176051-47F561D1-95D1-43AD-BF26-2A823DCFDEE1 Q38197284-568176B0-51DB-4EC6-9103-19A9A0A1A5E1 Q38649844-C13EC70C-B902-4CE6-BBFB-09C8D404D2EF Q38918303-AFD7DC54-6EDC-4683-A1E1-35ADF1294D0C Q38963389-35CC7E41-087A-4469-A675-A6CB898F44B8 Q39639310-9632D08E-B1DA-44F3-AE74-E3742D3DFC30 Q39666574-96D9ED74-1E2C-48F2-9CE8-673E1FDF0ED9 Q39760801-4647BB98-1011-47AF-810E-3AB21597AD09 Q40353496-57292D5F-D17C-4E51-BFDB-8EE966FEEE84 Q41845201-D3357894-F047-4D11-98E5-618C0ED6ABA0 Q42282480-577F7E2B-ED6C-4A0D-8695-0593C9E30774 Q47943718-B70AF030-EA83-40C8-9A04-9A0A443419BB Q48308026-E2916D0B-3CFD-49BC-9365-DDC2358CA24E Q50036781-F01BF217-90FD-4614-B6C2-D1DBE4627236 Q50871327-F19EDB98-327B-4A09-A3FD-E72F3CCDD596 Q51080164-A32E1B3D-FF63-434E-9A79-E15BA056F6B6

P2860

Prediction of hepatic clearance in human from in vitro data for successful drug development.

http://www.wikidata.org/entity/Q33437736

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prediction of hepatic clearanc ...... r successful drug development.

@ast

Prediction of hepatic clearanc ...... r successful drug development.

@en

type

label

Prediction of hepatic clearanc ...... r successful drug development.

@ast

Prediction of hepatic clearanc ...... r successful drug development.

@en

prefLabel

Prediction of hepatic clearanc ...... r successful drug development.

@ast

Prediction of hepatic clearanc ...... r successful drug development.

@en

P1433

Q33437736-25743967-8832-410A-AE98-4F640C342D90

P1476

Q33437736-BB00CFAA-E923-4C3A-BDB4-6CDDDCB41ED7

P2093

Q33437736-53152F1A-9FD7-4A77-9BD4-754B0129FE4C

Q33437736-6DBE7081-36D8-46ED-9955-8F31FF357A5E

Q33437736-A58D41D7-CF83-46C3-B3E6-41AF4225FD56

P2860

Q33437736-03123BFD-6EEA-4FAF-8E6C-27140B3B7626

Q33437736-03C8C156-37EF-4328-B690-5E2F9C50F527

Q33437736-045A2F21-09D2-4D26-8184-B772D2137907

Q33437736-056BFAEF-5438-4BAE-8C28-490ED65EFB53

Q33437736-068A5E9D-D192-4EAD-8860-C9268B19EF76

Q33437736-08AA0DF6-2110-443D-8F86-E3E7A2AB8007

Q33437736-0AFDCCAE-EDB1-464F-9A67-AFC6585F8F61

Q33437736-0C692680-F20D-4888-B147-65B1624789B6

Q33437736-0CE9CCCF-6C82-46C1-AE0B-A1284D6C1BBE

Q33437736-0D2E24FD-AB62-4DD4-BD2D-7A45745991D1

P2888

Q33437736-F498C078-4060-4EE8-B1ED-D6A5EC03F753

P304

Q33437736-D971D464-5277-44D1-B902-860719A3906C

P31

Q33437736-DB5A05F7-61D7-4BC9-BED7-FF7A332A9683

P356

Q33437736-F051196D-9F9C-4506-B34D-5BC3D5059CA3

P407

Q33437736-9BF91E24-F448-4E0F-A35F-C6800308AB21

P433

Q33437736-9F5EFD1E-CB84-4C77-BF8A-BB107560EA47

P478

Q33437736-B1BF2BF9-5902-4297-9237-BB5ADA90AD4F

P577

Q33437736-2FA1B904-85E8-4795-A7D6-8E01D7DCEA25

P5875

Q33437736-E8D5EAC5-BC7C-41A0-857D-23A676291C34

P6179

Q33437736-007BD2EA-93E9-4E7A-9139-DF1F7442B610

P698

Q33437736-8B6FD3C9-1ACB-4A8E-879B-94C520490300

P932

Q33437736-E69525D8-E7C4-4FFB-9F06-E21DE7DD2653

P356

S12248-009-9103-6

P1433

The AAPS Journal

P1476

Prediction of hepatic clearanc ...... r successful drug development.

@en

P2093

Masato Chiba

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Ishii

http://www.w3.org/2001/XMLSchema#string

Yuichi Sugiyama

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver

Immunoquantitation of FMO1 in human liver, kidney, and intestine

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

Current progress on esterases: from molecular structure to function

Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts

Human carboxylesterase isozymes: catalytic properties and rational drug design

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04

Can the pharmaceutical industry reduce attrition rates?

P2888

s12248-009-9103-6

P304

262-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-009-9103-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24395019

http://www.w3.org/2001/XMLSchema#string

P6179

1014694082

http://www.w3.org/2001/XMLSchema#string

P698

19408130

http://www.w3.org/2001/XMLSchema#string

P932

2691463

http://www.w3.org/2001/XMLSchema#string